Greer Katarina B, Blum Andrew E, Faulx Ashley L, Deming Erica M, Hricik Lauren L, Siddiqui Hinnah, Wilson Brigid M, Chak Amitabh
Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
Am J Gastroenterol. 2025 Mar 1;120(3):545-553. doi: 10.14309/ajg.0000000000002962. Epub 2024 Jul 11.
Although rates of esophageal adenocarcinoma (EAC) in the United States continue to rise, many patients at risk of disease are not screened. EsoCheck (EC), a nonendoscopic esophageal balloon sampling device coupled with EsoGuard (EG), a DNA-based screening assay, is an US Food and Drug Administration-approved minimally invasive alternative to the traditional screening method of upper endoscopy. The objective of this study was to prospectively determine the diagnostic accuracy, tolerance, and acceptability of the EC/EG test in a screening population.
We recruited veterans who met the American College of Gastroenterology Guideline criteria for endoscopic Barrett's esophagus (BE) and EAC screening at the Louis Stokes Cleveland Veterans Affairs Medical Center. All study participants completed unsedated EC-guided distal esophageal sampling followed by a sedated esophagogastroduodenoscopy (EGD). Diagnostic yield of the EG assay and EGD was recorded and used in calculation of sensitivity and specificity of EC/EG in prospective screening. The abbreviated Spielberger State-Trait Anxiety Inventory questionnaire was administered before and after completion of EC. Overall tolerance of EC sampling was evaluated on a 10-point Likert scale.
Esophageal cancer screening was accepted by 130 of 782 eligible veterans (16.6%), and we analyzed results of those who completed both screening tests (N = 124). Prevalence of BE/EAC among studied veterans was 12.9% (16/124), based on EGD. Sensitivity and specificity of EC/EG for EGD-detected BE/EAC were 92.9% (95% confidence interval [CI] 66.1-99.8) and 72.2% (95% CI 62.1-80.8), respectively. Positive and negative predictive values were 32.5% (95% CI 18.6-49.1) and 98.6% (95% CI 92.4-100), respectively. Baseline Spielberger State-Trait Anxiety Inventory-6 scores were reflective of notable levels of anxiety among veterans in the periprocedural setting. The mean postprocedure acceptability score for the EC test was 7.23 (SD 2.45).
Our data suggest excellent sensitivity and negative predictive value of EC/EG in a screening population of veterans, making this modality a powerful screening tool for BE and EAC.
尽管美国食管腺癌(EAC)的发病率持续上升,但许多有患病风险的患者并未接受筛查。EsoCheck(EC)是一种非内镜食管球囊采样装置,与基于DNA的筛查检测方法EsoGuard(EG)相结合,是一种经美国食品药品监督管理局批准的、可替代传统上消化道内镜筛查方法的微创检测手段。本研究的目的是前瞻性地确定EC/EG检测在筛查人群中的诊断准确性、耐受性和可接受性。
我们在路易斯·斯托克斯·克利夫兰退伍军人事务医疗中心招募了符合美国胃肠病学会内镜下巴雷特食管(BE)和EAC筛查指南标准的退伍军人。所有研究参与者均在未使用镇静剂的情况下完成了由EC引导的食管远端采样,随后接受了使用镇静剂的食管胃十二指肠镜检查(EGD)。记录EG检测和EGD的诊断率,并用于计算EC/EG在前瞻性筛查中的敏感性和特异性。在完成EC前后,对参与者进行简化版的斯皮尔伯格状态-特质焦虑量表问卷调查。EC采样的总体耐受性采用10分制李克特量表进行评估。
782名符合条件的退伍军人中有130人(16.6%)接受了食管癌筛查,我们分析了完成两项筛查检测的患者(N = 124)的结果。根据EGD结果,研究退伍军人中BE/EAC的患病率为12.9%(16/124)。EC/EG对EGD检测到的BE/EAC的敏感性和特异性分别为92.9%(95%置信区间[CI] 66.1 - 99.8)和72.2%(95% CI 62.1 - 80.8)。阳性预测值和阴性预测值分别为32.5%(95% CI 18.6 - 49.1)和98.6%(95% CI 92.4 - 100)。基线斯皮尔伯格状态-特质焦虑量表-6评分反映了退伍军人在围手术期的显著焦虑水平。EC检测的术后平均可接受性评分为7.23(标准差2.45)。
我们的数据表明,EC/EG在退伍军人筛查人群中具有出色的敏感性和阴性预测值,使其成为BE和EAC的有力筛查工具。